Autor: |
Terry D. Schneekloth, MD, Juan P. Arab, MD, Douglas A. Simonetto, MD, Tanya M. Petterson, MS, Shehzad K. Niazi, MD, Daniel K. Hall-Flavin, MD, PhD, Victor M. Karpyak, MD, PhD, Bhanu P. Kolla, MD, James E. Roth, MD, Walter K. Kremers, PhD, Charles B. Rosen, MD |
Jazyk: |
angličtina |
Rok vydání: |
2021 |
Předmět: |
|
Zdroj: |
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 5, Iss 6, Pp 1153-1164 (2021) |
Druh dokumentu: |
article |
ISSN: |
2542-4548 |
DOI: |
10.1016/j.mayocpiqo.2021.10.005 |
Popis: |
Objective: To assess the impact of standardized pretransplant alcohol abstinence and treatment guidelines on liver transplant outcomes. Methods: This study assessed the posttransplant relapse and survival associated with a pretransplant guideline mandating alcohol abstinence, addiction treatment, and Alcoholics Anonymous (AA) attendance. This retrospective cohort study included liver recipients with alcohol-induced liver disease transplanted between January 1, 2000, and December 31, 2012, at a Midwest transplant center. Cox regression models tested for associations between pretransplant treatment, demographic and clinical characteristics, and outcome measures. Results: Of 236 liver recipients (188 [79.7%] male; 210 [89%] white; mean follow-up, 88.6±55.0 months), 212 (90.2%) completed pretransplant treatment and 135 (57.2%) attended AA weekly. At 5 years, 16.3% and 8.2% had relapsed to any alcohol use and to high-dose drinking, respectively. Smoking during the 6 months before transplant was associated with any relapse (P=.0002) and high-dose relapse (P |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|